Skip to content
Research/Metabolic Glp1/Tirzepatide

Tirzepatide

compound

preliminary evidencePublic

FDA-approved dual incretin mimetic (GLP-1 + GIP). Demonstrated superior weight loss (~20-22%) and glycemic control versus semaglutide in head-to-head trials. Brand names: Mounjaro, Zepbound.

Category: Metabolic Glp1·Updated 5/20/2026
OverviewScienceClinicalSafetyPapersProtocolsOutcomes

Tirzepatide

FDA-approved dual incretin mimetic (GLP-1 + GIP). Demonstrated superior weight loss (~20-22%) and glycemic control versus semaglutide in head-to-head trials. Brand names: Mounjaro, Zepbound.

ScienceComing soon
ClinicalComing soon
SafetyComing soon
PapersComing soon
ProtocolsComing soon
OutcomesComing soon